Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of
chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly
Paclitaxel to determine the difference in progression free survival between the 2 groups. If
results at that stage suggest a potential benefit then the trial will be developed further to
accrue 70 more patients.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust